

Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients

NCT06691893

Status	RECRUITING
Phase	Phase 3
Sponsor	Massachusetts General Hospital
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (5)

- Patient diagnosed with moderate or severe exocrine pancreatic insufficiency (EPI), as defined using the Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) symptom score of 1.4 or greater.
- Patient diagnosed with acute, recurrent acute pancreatitis or subacute pancreatitis. Subacute pancreatitis is defined as recent diagnosis of acute pancreatitis with sequelae of the acute episode including infection, pseudocyst, walled-off pancreatic necrosis.
- Patient is currently admitted to the hospital at the time of study enrollment.
- Patient requiring at least 50% of daily caloric and fluid intake through enteral tube feeds.
- Patient is able and willing to provide informed consent.

Exclusion (5)

- Patient with chronic pancreatitis
- Patient is currently intubated and unable to provide consent
- Patient with active gastrointestinal tract cancer
- Patient requiring less than 50% of nutritional support at time of enrollment
- Patient is unable to tolerate any form of enteral nutrition

Locations (1 total)

Massachusetts General Hospital, Boston, Massachusetts, United States